UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 7599 Anagram Drive Eden Prairie, MN 55344 (Address of Principal Executive Offices) (Zip Code) Registrant's Telephone Number, Including Area Code: 952-426-1383 Not Applicable (Former name, former a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-40439 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) (State or Ot ...

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q1 2023 Earnings Conference Call February 14, 2023 4:30 AM ET Company Participants Dave Rosa - President and CEO Ron McClurg - CFO Conference Call Participants Alex Nowak - Craig Hallum Capital Group Ben Haynor - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. And welcome to the NeuroOne Medical Technologies Corporation First Quarter Fiscal Year 2023 Financial Results Conference Call. Today's call will be conducted by ...

Financial Performance - As of December 31, 2022, the company had an accumulated deficit of $52.6 million, primarily due to research and development expenses and interest expenses [122]. - The company recognized revenue of $1,455,188 during the three months ended December 31, 2022, related to the completion of the sEEG exclusivity maintenance milestone [139]. - Product revenue for the three months ended December 31, 2022, was approximately $114,579, compared to $33,748 for the same period in 2021, representing an increase of 80,831 [148]. - Collaborations revenue increased significantly to $1,455,188 for the three months ended December 31, 2022, from $6,374 in the prior year, marking an increase of 1,448,814 [148]. - The net loss for the three months ended December 31, 2022, was $1,732,769, a decrease of $1,074,706 compared to a net loss of $2,807,475 for the same period in 2021 [148]. - The net loss for the three months ended December 31, 2022, was $1.7 million, partially offset by approximately $0.3 million in non-cash expenses [173]. - The net decrease in cash for the three months ended December 31, 2022, was $3.5 million, contrasting with an increase of $9.3 million in the same period of 2021 [172]. Expenses and Cash Flow - The company expects to continue incurring significant expenses and increasing operating losses until a higher level of revenue from commercial sales is achieved [123]. - Research and development expenses rose to $1,563,496 for the three months ended December 31, 2022, up from $1,060,462 in the same period of 2021, reflecting an increase of $503,034 [153]. - Selling, general and administrative expenses remained stable at $1,663,737 for the three months ended December 31, 2022, compared to $1,742,141 in the prior year, showing a decrease of $78,404 [148]. - Net cash used in operating activities was $3.5 million for the three months ended December 31, 2022, compared to $2.7 million for the same period in 2021, indicating an increase in cash outflow [173][174]. - Net cash used in financing activities was $16,000 for the three months ended December 31, 2022, compared to net cash provided of $12.0 million in the same period of 2021 [178]. - The cash use from changes in operating assets and liabilities for Q4 2022 was primarily due to a decrease in deferred revenue and an increase in inventory purchases [173]. Development and Agreements - The company commenced commercial sales of cEEG strip/grid and electrode cable assembly products in the first quarter of fiscal year 2021, with sEEG depth electrode products launched in late calendar 2022 [120]. - The company entered into a development and distribution agreement with Zimmer, which included an upfront payment of $2.0 million and a subsequent payment of $3.5 million in August 2022 [134]. - The company is responsible for all development activities under the Zimmer Development Agreement, while Zimmer handles commercialization costs [132]. - The company is targeting the first quarter of 2023 for design verification of new hardware for its diagnostic and ablation depth electrode [119]. - The company anticipates generating additional revenue from the sale of products based on Evo cortical technology [127]. - The company has received FDA 510(k) clearance for its Evo cortical technology and Evo sEEG electrode technology, enhancing its product offerings [118][139]. Future Outlook and Concerns - The company anticipates significant increases in research and development expenses in the coming years to support the development of its cortical strip, grid electrode, and depth electrode technologies [144]. - The company has substantial doubt about its ability to continue as a going concern, necessitating additional funding through equity or debt financings [169]. - The company has been affected by global economic conditions, including the COVID-19 pandemic and increased inflation, which may impact future capital raising efforts [125][126]. - The company has entered into a Capital on Demand Sales Agreement allowing for an aggregate offering price of up to $14.5 million, with no issuances of securities having occurred to date [157]. Accounting and Financial Reporting - The financial statements are prepared in accordance with U.S. generally accepted accounting principles, requiring estimates and judgments that may affect reported amounts [179]. - The company continues to evaluate its accounting policies and practices in light of recent accounting pronouncements [185]. - The company incurred deferred issuance costs related to the ATM in Q4 2022 [178]. - The company has not experienced significant variable consideration adjustments related to product revenue to date [180].

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q4 2022 Results Conference Call December 13, 2022 4:30 PM ET Company Participants Dave Rosa - President and Chief Executive Officer Ron McClurg - Chief Financial Officer Operator Ladies and gentlemen, thank you for standing by. And welcome to the NeuroOne Medical Technologies Corporation Corporate Update Conference Call. Today's call will be conducted by the company's Chief Executive Officer, Dave Rosa; and Chief Financial Officer, Ron McClurg. Before ...

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q3 2022 Earnings Conference Call August 11, 2022 5:30 PM ET Company Participants Dave Rosa - President and Chief Executive Officer Ron McClurg - Chief Financial Officer Conference Call Participants Alexander Nowak - Craig-Hallum Capital Group Ben Haynor - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. And welcome to the NeuroOne Medical Technologies Corporation Third Quarter of Fiscal Year 2022 Financial Results Conf ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-40439 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) (State or Oth ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-40439 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) Delaware 27- ...

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q1 2022 Results Conference Call February 14, 2022 4:30 PM ET Company Participants Dave Rosa - Chief Executive Officer Ron Mcclurg - Chief Financial Officer Conference Call Participants Alex Knopick - Craig-Hallum Capital Ben Haynor - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by and welcome to the NeuroOne Medical Technologies Corporation First Quarter of Fiscal 2022 Earnings Conference Call. Today's call will be con ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2021 OR Registrant's Telephone Number, Including Area Code: 952-426-1383 Not Applicable ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 000-54716 NeuroOne Medical Technolog ...